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Three patients (2 IM/HU, 1IM) were lost to follow-up. As prospectively designed,
all available IM/HU patients (n=77) were analyzed together. According to the
study protocol, patients from the CML IV study were to be added to obtain
equal numbers for analysis. To arrive at a total of 77 IM patients, from study IV
another 49 patients were selected by propensity score matching. The median
age of the 154 patients was 55 years (range 18 – 82). The ELTS prognostic
score was available for 141 patients and was high in 8 (5.7%), intermediate in
35 (24.8%) and low in 98 (69.5%), with no significant differences between treat-
ment groups.
Results: The 5-year overall survival (OS) / progression-free survival (PFS)
probabilities were 90.4 and 86.7% in the IM/HU and twice 84.9% in the IM
arm (p=not significant). With IM/HU, the probabilities of complete cytogenetic
response (CCR) at 6, 12, and 18 months were 54.3, 84.0, and 93.7%. In the
IM arm, the corresponding numbers were 70.4, 84.9, and 83.3% (p=not sig-
nificant). Primary endpoint was MMR rate at 18 months. There was no sig-
nificant difference between IM/HU (65.8%) and IM (66.0%). At 6 months,
MMR rates were 21.6 (IM/HU) vs 41.1% (p=0.0383) and at 12 months 41.9
(IM/HU) vs 58.9% (not significant). Time to event analyses of OS and PFS
did not result in significant differences; neither did group comparisons
between the probabilities of CCR and MMR. The median HU dose was
500mg (range 152-3000); the median IM dose was 400 mg (range 145-
617mg) in both arms. The gross numbers of adverse events in general or of
adverse events of grade 4 were not different between the two arms, but
cumulative incidences showed an earlier occurrence in the IM/HU than in
the IM arm (p= 0.0343, Gray test)
Summary/Conclusions: Compared to Imatinib only, the combination of Ima-
tinib and HU resulted in a lower MMR rate at 6 months but a similar MMR rate
at 18 months. Furthermore, IM/HU was associated with more early adverse
events. There was no indication of a beneficial effect in the treatment of CML
patients in 1st chronic phase using the combination of IM with HU.
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Background: The efficacy of branded imatinib (Gleevec) in the first-line treat-
ment of chronic myeloid leukemia (CML) has been demonstrated in several
clinical studies. However, there are few consistent data in the literature on the
efficacy and adverse effects of generic formulations of imatinib. In Brazil, CML
patients have been treated in the national public health system with generic
imatinib since June 2013. 
Aims: The present study aims to evaluate the efficacy and safety of generic
imatinib in the treatment of CML in comparison with the reference drug
(Gleevec) in the first three months of imatinib treatment.
Methods: This is a multicenter, observational, ambispective, cohort-type study.
The study was initiated in January 2015 with the intended participation of 17
Brazilian centers. In the prospective group, were selected chronic phase CML
patients who started their first-line treatment with generic imatinib between
January 2015 and October 2016, whereas retrospective group was treated
with Gleevecbetween January 2010 and December 2011. All patients started
imatinib less than six months from diagnosis. Study data were collected and
managed using REDCap electronic data capture tools. Demographic data were
collected at diagnosis: age, gender, Sokal, Hasford, EUTOS score, comorbidi-
ties, cytogenetics, BCR-ABL transcript type. The definition of the responses
followed the European Leukemia Net 2013 criteria. Adverse events were
assessed based on the Common Terminology Criteria for Adverse Events
(CTCAE) Version 4.0.3, 2010. Statistical analysis: SPSS version 21.0 was
used applying the chi-square and t-test, when adequate. All analysis considered
p-value <0.05 as significant.
Results: Ten centers have registered 177 patients in the retrospective group
and 68 patients in the prospective group so far. For this preliminary analysis,
response data from 132 patients were available (47 from prospective and 85
from the retrospective groups). The median age of patients was 54 years in
the prospective group and 46 years in the retrospective group (P=0.12). Sokal
score in prospective and retrospective groups, respectively: low risk
42%/52%; intermediate risk 42%/31% and high risk 45%/67% (P=0.48).
There was no difference between the groups concerning gender, Hasford,
EUTOS scores, ECOG, blood cell counts at diagnosis and before starting
imatinib and BCR-ABL transcripts. Regarding responses, there was no dif-
ference in the hematological, complete cytogenetic responses and rate of
BCR-ABL transcripts >10% at three months. However, there was a higher
rate of failure at three months according to the ELN 2013 criteria in the
prospective group (14.9% versus 4.7% Gleevec group, P=0.04). There was
no significant difference in grade 3 and 4 hematological and non-hematolog-
ical toxicity, but there was one early death in the prospective group (acute
peripheral arterial occlusion and renal failure). Four patients discontinued
imatinib: one from Gleevec group (resistance) and three from the generic
group due to intolerance (1) and resistance (2). 
Summary/Conclusions: According to ELN-2013 criteria, there was a higher
rate of failure in the prospective group (generic Imatinib) at three months, but
no difference in toxicity. The register is ongoing; the confirmation of this data
and the impact in prognosis will be evaluated in the long-term follow-up, after
increasing the number of patients. 
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Background: Additional chromosomal aberrations (ACA) as marker of clonal
evolution in chronic myeloid leukemia (CML) patients were previously noted in
association with resistance to therapy. The presents of ACA have been asso-
ciated with a worse prognosis for survival in the pre-TKI era. The ACA classi-
fication proposed earlier was based only on its frequencies. Whereas ACA’s
clinical impact had not yet been clearly established.
Aims: The aim of our study was to evaluate the long-term impact of the ACA
presence in Ph-positive cells in CML patients on TKI treatment results.
Methods: 30 patients with ACA in Ph-positive cells treated in our center from
2005 to 2015 years were included in this study. Cytogenetic analyses of at
least 20 Giemsa-banded bone marrow metaphases were interpreted per
ISCN 2013. We analyzed overall survival (OS) and cumulative incidence of
CML-related death on TKI treatment. Cox regression was used for multivari-
ate survival analysis, that included next covariates: number of ACA, type of
ACA, age, TKI type, CP or AP at diagnosis. OS was estimated by Kaplan-
Meier method with log-rank test for comparison. Cumulative incidence of
CML-related death was estimated into consideration the presents of com-
peting risks (CML-unrelated death) using Gray’s test for comparison between
groups. 
Results: Median follow-up period in ACA group (n=30) was 51 months (3-
124). ACA at diagnosis were detected in 16 (53%) of 30 patients. Chronic
phase CML at diagnosis was determined in 23 (77%) patients. Imatinib was
used as first-line in 20 (67%) patients, 3 (10%) patients were initially treated
with Nilotinib. Accelerated phase was defined in 7 (23%) patients. In that
group treatment of 6 patients was started with Imatinib and Dasatinib was
given initially for one patient. «Major-route» ACAs (trisomy 8,
+der(22)t(9;22)(q34;q11), i(17)(q10), trisomy 19,) were detected in 16 (53%)
of 30 patients. Complex aberrations (2 ACA and more) were revealed in 7
(23%) patients, 4 patients from this group had «major-route» ACA. 10-years
OS in the whole ACA group was 67%, 10-years cumulative incidence of CML-
related death was 23%. Number of ACA (p=0.03, HR=13.2) and age (p=0.03,
HR=1.14) had statistical significance influence on survival by regression
analysis. 10-years OS was 31% and 77% (p<0.05) in patients with complex
ACA and single ACA respectively, 10-years cumulative incidence of CML-
related death was 54% for patients with complex aberrations versus 10% for
single ACA patients (p<0.05) (Figure 1).
Figure 1.
Summary/Conclusions: Our results showed that TKI treated CML patients
with complex ACAs have a higher risk of progression and death in comparison
with single-ACA patients. 
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